What is Pathalys Pharma?
Pathalys Pharma, Inc. operates as a private, late-stage clinical biopharmaceutical entity dedicated to the innovation of advanced therapeutic solutions. The company is specifically focused on the management of ESKD, a sector characterized by high barriers to entry and significant patient demand for novel interventions. By leveraging a specialized clinical development model, Pathalys Pharma bridges the gap between cutting-edge scientific research and commercial-ready medical applications. Its market position is defined by a commitment to addressing chronic conditions that require sophisticated, targeted pharmacological approaches, positioning the firm as a high-value target for strategic partnerships and long-term institutional investment.
How much funding has Pathalys Pharma raised?
Pathalys Pharma has raised a total of $255M across 2 funding rounds:
Debt
$150M
Series B
$105M
Debt (2023): $150M with participation from Carlyle Group, Catalys Pacific, DaVita, Abingworth, and OrbiMed
Series B (2024): $105M led by Catalys Pacific, TCG Crossover, and Samsara BioCapital
Key Investors in Pathalys Pharma
Catalys Pacific
Catalys Pacific is a venture firm focused on transforming life sciences innovation by creating and investing in global biotech companies, with a specific emphasis on targeted therapies for chronic kidney disease.
TCG Crossover
TCG Crossover is a science-driven investment firm that specializes in advancing disruptive medicines and supporting breakthrough therapies with the potential to transform the healthcare landscape.
Samsara BioCapital
Samsara BioCapital partners with scientists and drug developers to create transformative therapeutics, leveraging deep industry experience to drive innovation in the biopharmaceutical sector.
What's next for Pathalys Pharma?
With the successful closure of this latest funding round, Pathalys Pharma is well-positioned to advance its lead candidates through the final stages of clinical validation. The strategic focus will likely shift toward regulatory engagement, manufacturing scale-up, and the preparation of commercial infrastructure. Given the company's current lifecycle stage, the management team is expected to prioritize data readouts that will serve as the foundation for future market authorization. Furthermore, the continued support from its diverse investor base—ranging from venture-focused life science firms to strategic healthcare partners—suggests a clear path toward either a potential public offering or a strategic acquisition by a larger pharmaceutical entity looking to bolster its renal health portfolio. The company remains a focal point for stakeholders monitoring the intersection of biotechnology innovation and specialized healthcare delivery.
See full Pathalys Pharma company page
